RxDoctor Payments Data

Sevak Ohanian, MD

Neurology · Katy, TXNPI 1922180637

Payments from drug & device makers

$18,688in general payments, 2019–2025

Across 1,131 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • SK Life Science, Inc.$1K
  • Boston Scientific$938
  • Amneal Pharmaceuticals LLC$840
  • Abbott$752
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1071%
  • Food & beverage$18,49099%
  • Education$910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)147$1,949
Teva Pharmaceuticals USA, Inc.128$1,293
SK Life Science, Inc.77$1,273
Boston Scientific33$938
Amneal Pharmaceuticals LLC59$840
Abbott26$752
Lilly USA, LLC46$749
AstraZeneca(2 entities)35$742
Pfizer61$705
Argenx US, Inc.30$644
Eisai Inc.30$607
Novartis34$548
UCB, Inc.34$547
Lundbeck LLC28$502
Sunovion Pharmaceuticals Inc.29$387
MDD US Operations, LLC18$379
Acadia Pharmaceuticals Inc20$338
Genentech USA, Inc.20$333
Supernus Pharmaceuticals, Inc.19$330
Neurocrine Biosciences, Inc.18$321
Amgen(2 entities)20$309
Biohaven Pharmaceuticals, Inc.16$302
Biohaven Pharmaceutical Holding Company Ltd.20$291
Biogen21$284
Acorda Therapeutics, Inc8$224
Avanir Pharmaceuticals, Inc.14$221
Kyowa Kirin, Inc.7$209
Sanofi6$198
Sumitomo Pharma America, Inc.11$178
Vertiflex, Inc.3$145
Corium, LLC8$143
Mallinckrodt Enterprises LLC7$127
Grifols USA, LLC5$116
Tanabe Pharma America, Inc.7$111
EMD Serono, Inc.6$106
Axsome Therapeutics, Inc.4$96
Aucta Pharmaceuticals, Inc.6$96
Otsuka America Pharmaceutical, Inc.5$92
Neurelis, Inc.3$91
Jazz Pharmaceuticals Inc.4$84
Adamas Pharmaceuticals, Inc.5$82
Arbor Pharmaceuticals, Inc.4$71
Collegium Pharmaceutical, Inc.3$69
Medtronic3$64
Takeda Pharmaceuticals U.S.A., Inc.3$62
Catalyst Pharmaceuticals, Inc.4$62
Bristol Myers Squibb3$53
Impel Pharmaceuticals Inc.3$52
Mallinckrodt Hospital Products Inc.3$52
Assertio Therapeutics, Inc.3$49
Avion Pharmaceuticals2$44
Azurity Pharmaceuticals, Inc.2$41
Vanda Pharmaceuticals Inc.2$40
Promius Pharma LLC2$38
Upsher-smith Laboratories LLC2$38
Johnson & Johnson(2 entities)2$35
GE HealthCare1$32
Shire North American Group Inc2$32
Harmony Biosciences LLC1$24
E.r. Squibb & Sons, L.L.C.1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,688 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$209,628
Medicare patients
487
Services billed
2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab31$1,018,171
RytaryCarbidopa/Levodopa498$396,644
IngrezzaValbenazine Tosylate13$142,123
BotoxOnabotulinumtoxina96$129,102
XcopriCenobamate38$54,956
Memantine Hcl ErMemantine Hcl471$44,992
Rivastigmine176$32,843
HorizantGabapentin Enacarbil13$29,452
Emgality PenGalcanezumab-Gnlm32$28,018
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone186$27,829
NeuproRotigotine24$26,901
Nurtec OdtRimegepant Sulfate20$26,627
Ropinirole ErRopinirole Hcl274$23,159
Topiramate ErTopiramate12$22,611
Pramipexole ErPramipexole Di-Hcl69$22,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$742$1,018,17131 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$840$400,998576 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$321$159,10724 claims
AbbVieBotox, Namzaric$1,949$136,143107 claims
SK Life Science, Inc.Xcopri$1,273$54,95638 claims
Arbor Pharmaceuticals, Inc.Horizant$71$29,45213 claims
UCB, Inc.Neupro$547$26,90124 claims
PfizerNurtec Odt$705$26,62720 claims
Sunovion Pharmaceuticals Inc.Aptiom$387$14,94712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →